NewsMeter
A positive advisory committee vote on Replimune's lead drug candidate lifted the company's shares. Advisory panels review clinical and safety data before a final regulatory determination.
What the advisory committee does Panels like this convene to evaluate a drug's evidence package and vote on whether the data support its intended use.
Their determinations are advisory, not binding, but regulators follow positive recommendations at a high rate. That track record is why a favorable vote moves markets.
Market response Replimune shares rose following the panel's decision. Drug stocks respond immediately to advisory outcomes because the vote is the most transparent public checkpoint before a final regulatory call.
Keep reading